Responses

Extended report
Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

  • Published on:
    Response to Dr Bolland's eLetter

    Dear Editor,

    The work carried out by the authors on calcium and the cardiovascular risk is of primary importance. We thank the authors for questions and comments on the SEKOIA study, safety being a primary concern for us.
    The number of emergent adverse events reported in SEKOIA study was similar in the 3 treatments groups: 85.8%, 87.9% and 86.5% in the SrRan 1g, SrRan 2g and placebo groups as well as the number...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind randomized, placebo-controlled trial

    Dear Editor,

    We would like to reply to the recent letter by Murphy et al(1) regarding the possible influence of obesity and weight changes on the results of the SEKOIA trial of the efficacy and safety of strontium ranelate in knee osteoarthritis.2 Obesity and overweight are recognized risk factors for osteoarthritis,3 and so it is essential to include such patients in studies of potential treatments, since they are...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Strontium and cardiovascular events
    • Mark J Bolland, Senior Research Fellow
    • Other Contributors:
      • Andrew Grey

    Dear Editor,

    In the report of their trial of strontium ranelate in knee osteoarthritis, Reginster and colleagues state that "Strontium ranelate was well tolerated" and that "The safety profile of strontium ranelate was satisfactory, in line with knowledge of this agent" (1). However, contemporaneously, the European Medicines Agency recommended that the use of strontium ranelate be restricted because it increased the r...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial
    • Claire-Louise Murphy, Rheumatology SpR
    • Other Contributors:
      • Eithne Murphy, Trevor Duffy, Miriam O'Sullivan, Maurice Barry

    Dear Editor,

    We read with interest the paper regarding Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo- controlled trial. We note the exclusion criteria included secondary knee osteoarthritis. On review of the results section it appears that many of the patients both the randomised and the intention to treat groups e.g. the stronti...

    Show More
    Conflict of Interest:
    None declared.